Processa Pharmaceuticals, Inc. Common PCSA
Key Stats
- Today's Range
- $2.05 – $2.22
- 50-Day Range
- $1.67 – $3.11
- 52-Week Range
- $1.67 – $14.24
- Volume
- 98K shs
- Average Volume
- 446K shs
- Market Cap
- $5.90 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 2.32
- Price / Sales
- —
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.00
About Processa Pharmaceuticals, Inc. Common
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
Related Stocks
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.